关键词： AAAAI, American Academy of Allergy, Asthma and Immunology ACAAI, American College of Allergy, Asthma and Immunology ACE2, Angiotensin-converting enzyme 2 ADCC, Antibody-Dependent Cell-mediated Cytotoxicity AEs, Adverse events Asthma BTS, British Thoracic Society Biologics COVID-19 COVID-19, Coronavirus Disease 2019 DNA, Deoxyribonucleic acid EBM, Evidence Based Medicine ELF, European Lung Foundation ERS, European Respiratory Society FDA, Food and Drug Administration GINA, Global Initiative for Asthma GSK, Glaxo Smith Kline ICS, inhaled corticosteroids ICU, Intensive Care Unit IL13, Interleukin 13 IL4, Interleukin 4 IL5, Interleukin 5 IL5Ra, Interleukin 5 alfa receptor IL5r, Interleukin 5 receptor IL6, Interleukin 6 IgE, Immunoglobulin E NHLBI, National Heart, Lung, and Blood Institute OCS, Oral corticosteroids PDGFRA, Platelet-Derived Growth Factor Receptor A PROSE study, Preventative Omalizumab or Step-up therapy for fall Exacerbations study Pandemic RCTs, Randomized Controlled Trials SAEs, Serious Adverse Events SARP, Severe Asthma Research Programme SARS-CoV-2 SARS-CoV-2, Severe Acute Respiratory Syndrome Coronavirus 2 SC, Subcutaneous SIAAIC, Italian Society of Allergy, Asthma and Clinical Immunology Severe T2, Type 2 inflammation TMPRSS2, Transmembrane Protease Serine 2 Enzyme Treatment USA, United States of America mAb, Monoclonal antibody

来  源：   DOI：10.1016/j.waojou.2020.100126   PDF(Sci-hub)   PDF(Pubmed)

Abstract：
Managing patients with severe asthma during the coronavirus pandemic and COVID-19 is a challenge. Authorities and physicians are still learning how COVID-19 affects people with underlying diseases, and severe asthma is not an exception. Unless relevant data emerge that change our understanding of the relative safety of medications indicated in patients with asthma during this pandemic, clinicians must follow the recommendations of current evidence-based guidelines for preventing loss of control and exacerbations. Also, with the absence of data that would indicate any potential harm, current advice is to continue the administration of biological therapies during the COVID-19 pandemic in patients with asthma for whom such therapies are clearly indicated and have been effective. For patients with severe asthma infected by SARS-CoV-2, the decision to maintain or postpone biological therapy until the patient recovers should be a case-by-case based decision supported by a multidisciplinary team. A registry of cases of COVID-19 in patients with severe asthma, including those treated with biologics, will help to address a clinical challenge in which we have more questions than answers.
摘要：
在冠状病毒大流行和COVID-19期间管理严重哮喘患者是一个挑战。当局和医生仍在学习COVID-19如何影响患有潜在疾病的人，严重的哮喘也不例外。除非相关数据出现，改变我们对哮喘患者在本次大流行期间所使用药物的相对安全性的理解，临床医生必须遵循现行循证指南的建议,以预防失控和急性加重.此外，由于缺乏表明任何潜在危害的数据，目前的建议是,在COVID-19大流行期间,对明确指征且有效的哮喘患者继续给予生物疗法.对于SARS-CoV-2感染的严重哮喘患者，维持或推迟生物治疗直到患者康复的决定应该是由多学科团队支持的逐案决策。重症哮喘患者的COVID-19病例登记，包括那些用生物制剂治疗的，这将有助于解决我们的问题多于答案的临床挑战。
公众号